Todd Franklin Watanabe Sells 15,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) insider Todd Franklin Watanabe sold 15,000 shares of the company's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $15.17, for a total transaction of $227,550.00. Following the completion of the transaction, the insider now owns 823,430 shares in the company, valued at $12,491,433.10. This represents a 1.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Arcutis Biotherapeutics Stock Down 0.1 %

Shares of NASDAQ ARQT traded down $0.02 during midday trading on Monday, reaching $14.97. 2,437,279 shares of the company's stock traded hands, compared to its average volume of 3,133,878. The company has a market cap of $1.75 billion, a price-to-earnings ratio of -8.36 and a beta of 1.32. The stock's 50 day simple moving average is $10.84 and its 200-day simple moving average is $10.06. The company has a quick ratio of 2.38, a current ratio of 2.46 and a debt-to-equity ratio of 0.67. Arcutis Biotherapeutics, Inc. has a one year low of $2.96 and a one year high of $15.79.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.09. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%. The business had revenue of $44.76 million for the quarter, compared to analysts' expectations of $38.05 million. On average, analysts predict that Arcutis Biotherapeutics, Inc. will post -1.34 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ARQT shares. Needham & Company LLC reissued a "buy" rating and issued a $18.00 price objective on shares of Arcutis Biotherapeutics in a research note on Thursday, November 7th. Jefferies Financial Group initiated coverage on Arcutis Biotherapeutics in a research report on Wednesday, August 28th. They set a "buy" rating and a $15.00 price target on the stock.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Rubric Capital Management LP lifted its holdings in shares of Arcutis Biotherapeutics by 30.7% during the 2nd quarter. Rubric Capital Management LP now owns 9,816,672 shares of the company's stock valued at $91,295,000 after purchasing an additional 2,306,672 shares during the last quarter. Candriam S.C.A. purchased a new stake in Arcutis Biotherapeutics in the second quarter valued at about $12,159,000. Perceptive Advisors LLC boosted its holdings in Arcutis Biotherapeutics by 107.8% in the second quarter. Perceptive Advisors LLC now owns 1,558,500 shares of the company's stock worth $14,494,000 after acquiring an additional 808,500 shares in the last quarter. Suvretta Capital Management LLC grew its stake in shares of Arcutis Biotherapeutics by 7.2% during the third quarter. Suvretta Capital Management LLC now owns 10,721,511 shares of the company's stock worth $99,710,000 after acquiring an additional 717,019 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Arcutis Biotherapeutics by 9.9% during the third quarter. State Street Corp now owns 5,641,631 shares of the company's stock valued at $52,467,000 after acquiring an additional 506,788 shares in the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.